Open Access. Powered by Scholars. Published by Universities.®
- Discipline
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Novel Mechanistic Insight Into The Anticancer Activity Of Cucurbitacin D Against Pancreatic Cancer (Cuc D Attenuates Pancreatic Cancer), Mohammed Sikander, Shabnam Malik, Sheema Khan, Sonam Kumari, Neeraj Chauhan, Parvez Khan, Fathi T. Halaweish, Bhavin Chauhan, Murali M. Yallapu, Meena Jaggi, Subhash C. Chauhan
Novel Mechanistic Insight Into The Anticancer Activity Of Cucurbitacin D Against Pancreatic Cancer (Cuc D Attenuates Pancreatic Cancer), Mohammed Sikander, Shabnam Malik, Sheema Khan, Sonam Kumari, Neeraj Chauhan, Parvez Khan, Fathi T. Halaweish, Bhavin Chauhan, Murali M. Yallapu, Meena Jaggi, Subhash C. Chauhan
School of Medicine Publications and Presentations
Pancreatic cancer (PanCa) is one of the leading causes of death from cancer in the United States. The current standard treatment for pancreatic cancer is gemcitabine, but its success is poor due to the emergence of drug resistance. Natural products have been widely investigated as potential candidates in cancer therapies, and cucurbitacin D (Cuc D) has shown excellent anticancer properties in various models. However, there is no report on the therapeutic effect of Cuc D in PanCa. In the present study, we investigated the effects of the Cuc D on PanCa cells in vitro and in vivo. Cuc D inhibited …
Therapeutic Efficacy Of A Novel Βiii/Βiv-Tubulin Inhibitor (Veru-111) In Pancreatic Cancer, Vivek K. Kashyap, Qinghui Wang, Saini Setua, Prashanth K.B. Nagesh, Neeraj Chauhan, Sonam Kumari, Pallabita Chowdhury, Duane D. Miller, Murali M. Yallapu, Wei Li, Meena Jaggi, Bilal B. Hafeez, Subhash C. Chauhan
Therapeutic Efficacy Of A Novel Βiii/Βiv-Tubulin Inhibitor (Veru-111) In Pancreatic Cancer, Vivek K. Kashyap, Qinghui Wang, Saini Setua, Prashanth K.B. Nagesh, Neeraj Chauhan, Sonam Kumari, Pallabita Chowdhury, Duane D. Miller, Murali M. Yallapu, Wei Li, Meena Jaggi, Bilal B. Hafeez, Subhash C. Chauhan
School of Medicine Publications and Presentations
Background: The management of pancreatic cancer (PanCa) is exceptionally difficult due to poor response to available therapeutic modalities. Tubulins play a major role in cell dynamics, thus are important molecular targets for cancer therapy. Among various tubulins, βIII and βIV-tubulin isoforms have been primarily implicated in PanCa progression, metastasis and chemo-resistance. However, specific inhibitors of these isoforms that have potent anti-cancer activity with low toxicity are not readily available.
Methods: We determined anti-cancer molecular mechanisms and therapeutic efficacy of a novel small molecule inhibitor (VERU-111) using in vitro (MTS, wound healing, Boyden chamber and real-time xCELLigence assays) and in vivo …